When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Polycystic kidney disease is a hereditary condition where multiple cysts develop within the renal tubules of the kidney, impairing their function. As the cysts grow, they compress nearby…
David L. Green, MD, PhD, MBA, founder and CEO of R3 Stem Cell International, discusses stem cell therapy for kidney failure in South Africa. He explains the function…
Dawn L. Sammons, DO; Joslyn R. Sciacca Kirby, MD, MS; Boni E. Elewski, MD; and David M. Pariser, MD, provide clinical and therapeutic #pearls in medical #dermatology.
